Salute e Benessere
Kedrion Biopharma closes 2024 with a growth of +10% and unveils its new identity
2024 was an important year for Kedrion, marking double-digit growth, with turnover reaching . EBITDA reported increased by 28% to 232 million Euro , while adjusted EBITDA rose by 20% to 279 million Euro . Additionally, improved margins and disciplined financial management generated positive cash flow, fully funding investments and strengthening operations.
These figures reflect a strategy that has made Kedrion a company with approximately and a . Kedrion's global headquarters are in Italy , and the group has affiliates in Europe , the United Kingdom , North America , Latin America , and Asia . The company operates a vast in the US and Europe . These plasma centers supply our , supporting an extensive portfolio of , positioning the company as the in the plasma-derived therapies sector.
Over the past years, Kedrion has consolidated its global leadership within the plasma-derived scenario, reinforcing its commitment to . The new Kedrion identity integrates all affiliates under one brand and reflects our ensuring better access to life-changing medicines.
The newly unveiled logo symbolizes a and encapsulates the essence of the company: its ability to create . Kedrion fosters connections between donors, patients, scientists, caregivers and family members. This hallmark characterises every innovation, investment, and operational improvement aimed at reaching more people worldwide.
Kedrion has always been dedicated to , in particular to find solutions for unmet medical needs. This commitment has enabled the company to provide worldwide for two extremely serious and rare diseases.
Today, our pipeline is expanding with and upcoming . The company is also exploring novel proteins for rare diseases, utilizing and to pave the way for future treatments.
Kedrion's commitment to using materials previously considered waste is part of a broader approach that sees the company strongly . We are advancing our to reduce our environmental footprint, and we are aligning with the Science Based Targets Initiative (SBTi), which sets ambitious targets for emission reduction and climate protection.
Our will be live starting today at 3 PM CET . Visitors will be able to explore on the site the company's new identity and narrative.
Kedrion Biopharma collects and fractionates blood plasma to produce and distribute plasma-derived therapies for rare, ultra-rare, and debilitating conditions like Coagulation and Neurological Disorders, Immunodeficiencies, and Rh sensitization. We employ approximately 5,200 people worldwide and our industrial network includes 68 plasma collection centers in the United States and 8 in the Czech Republic , and 7 production facilities across 5 countries. We are committed to creating a world where science and care know no bounds, partnering with the medical-scientific community, institutions, patient advocacy groups, and research bodies to foster innovation and improve care. Every connection we make impacts someone, somewhere.
This release includes "forward-looking statements," within the meaning of the securities laws and certain other jurisdictions, based on current expectations and projections about future events. All statements other than statements of historical facts included in this release, including, without limitation, statements regarding our future financial position, risks and uncertainties related to our business, strategy, capital expenditures and our plans and objectives for future operations, may be deemed to be forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties. Words such as "believe," "expect," "anticipate," "may," "assume," "plan," "intend," "will," "should," "estimate," "risk," "target," "objectives," "outlook," "probably," "project," "seek" and similar expressions or the negatives of these expressions are intended to identify forward-looking statements. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Any forward-looking statement speaks only as of the date on which it is made and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This release is for information purposes only and does not constitute an offer to sell or the solicitation of an offer to buy securities. This release does not contain all of the information that is material to an investor and is not required under the indenture dated May 3, 2023 entered into for the issuance of the 6½% senior secured notes due 2029.
Logo: https://mma.prnewswire.com/media/2662888/Kedrion_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/kedrion-biopharma-closes-2024-with-a-growth-of-10-and-unveils-its-new-identity-302427671.html